The abstract is read at the publisher; the summary is JClub's.
Fibrocytes make up nearly two-thirds of collagen-producing cells in bone marrow from patients with JAK2V617F-mutated myelofibrosis, exceeding myofibroblasts.
- Why it matters: Bone marrow fibrosis in JAK2V617F-mutated myelofibrosis has been viewed mainly as cytokine-driven from megakaryocytes and platelets, leaving fibrocyte contributions and targeted therapies insufficiently defined.
- What they did: The study quantified collagen-producing fibrocytes versus myofibroblasts in patient bone marrow, then used Jak2V617F transgenic mice for a high-throughput drug screen identifying statins, with pitavastatin tested in vivo and in patient-derived fibrocytes.
- The result: Pitavastatin reduced fibrocyte numbers, ameliorated bone marrow fibrosis, and improved anemia in Jak2V617F mice, while lowering TGF-β1 production and myofibroblast expansion; patient fibrocytes were similarly sensitive in vitro.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.